Therapies like selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs) have markedly enhanced survival outcomes by targeting estrogen signaling, a pivotal factor in tumor proliferation in HR+ breast cancer [4]. This evidence concerns the gene CYP19A1 and breast carcinoma.